This special advertising supplement did not involve the reporting or editing staff of the Los Angeles Business Journal.
LETTER FROM THE PUBLISHER

As fans and supporters of homegrown innovation here at the Los Angeles Business Journal, it’s my distinct honor and privilege to once again present the annual Patrick Soon-Shiong Innovation Awards for 2015.

In particular, it is with great admiration and respect for great ideas that we stand alongside the great Patrick Soon-Shiong, whose very name has become synonymous with groundbreaking innovation. This special award program was created with the vision to celebrate the organizations that continue to stretch boundaries.

The greater Los Angeles region has long been a thriving home to many of the most exciting and groundbreaking companies in the world—and today that is the case more than ever. We recognize that LA’s tremendous stew of ingenuity, innovation and creativity is what in many ways sparks the economic competitiveness of the region and brings a distinct and unique edge to our local economy.

Dr. Soon-Shiong himself has more than led by example—he’s a brilliant entrepreneur who has repeatedly illustrated how the innovative spirit can drive economic value. Moreover, he shares our desire to acknowledge and encourage innovation and has once again made the commitment to underwrite this prestigious award program.

This year, the awards were handed out at a ceremony on November 18th at the Four Seasons Hotel in Beverly Hills, where we were also excited to host a half-day symposium that will begin with breakfast and progress through a series of several terrific guest speakers. Our attendees had an opportunity to be inspired by local innovators and gain valuable expertise on generating some of the great ideas coming out of California. The evening portion of the event was highlighted by the Patrick Soon-Shiong Innovation Awards dinner, where we honored and acknowledged the people and organizations that continue to stretch the boundaries and have proven to be leaders in innovation.

Thanks to Dr. Soon-Shiong and the other terrific minds that played a role in helping us select our honorees from a pool of fascinating and inspirational finalists. Congratulations to this year’s five extraordinary honorees and seven exceptional finalists—each of whom continue to inspire us and provide invaluable contributions to keeping Los Angeles at the forefront of innovation.

Matthew A. Toledo
Publisher & CEO

AN ADVERTISING SUPPLEMENT TO THE LOS ANGELES BUSINESS JOURNAL NOVEMBER 23, 2015

DR. PATRICK SOON-SHIONG, INNOVATOR

A regular atop the Los Angeles Business Journal’s list of Wealthiest Angelenos, and a past recipient of the LABJ’s “Business Person of the Year” (thanks to his significant business successes and philanthropic contributions), Dr. Patrick Soon-Shiong is no stranger to the pages of our publication.

He knows as well as anyone that innovation, coupled with passion and hard work, is the engine for success in business—not to mention a catalyst for life-enhancing, or even life-saving activity.

His groundbreaking concepts for curing diabetes led to the first nanotechnology-based breast cancer drug, Abraxane, which is credited with saving thousands of lives. He’s since made time to research personalized drug therapies based on people’s gene sets, one of the hottest trends in research.

Now, for the sixth year, his love of innovation has prompted him to once again join the Business Journal in handing out Patrick Soon-Shiong Innovation Awards to deserving organizations that may in fact remind Soon-Shiong a little bit of his own early stages as a passionate entrepreneur and innovator.

We created this very special awards program to showcase Los Angeles as a place of innovation for businesses—and innovation in business nearly always leads to growth.

Here’s a closer look at the inspiration and name-sake of our innovation award:

Dr. Patrick Soon-Shiong is a physician, surgeon and scientist, has pioneered novel Therapies for both diabetes and cancer, published over 1000 scientific papers, and has over 95 issued patents on groundbreaking advancements spanning myriad fields.

Dr. Soon-Shiong performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. In 2014 Phase 3 trials revealed a 48 percent pathological complete remission in triple negative breast cancer with Abraxane treatment prior to surgery. Abraxane is now approved in many countries across the globe and sales are expected to reach a billion dollars in 2016.

From 1997 to 2010, Dr. Soon-Shiong served as founder, Chairman and CEO of two global pharmaceutical companies, American Pharmaceutical Partners and Abraxis BioScience. Both were acquired for multi-billion dollars in 2008 and 2010. In 2011 he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network, for the secure sharing of genetic and medical information—empowering doctors to treat patients with proven precision at the first point of care and, ultimately, improving the lives of individuals, everywhere.

Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation and Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He currently co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America. He is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award.
CONGRATULATIONS TO

Cargomatic
Jonathan Kessler

DAQRI
Regan Wynne

LEHR LLC
Bernardo Herzer,
David Kostkas &
Jeff Blum

Valencia Technologies Corporation
Stacy Chambliss

X-Therma Inc.
Xiaoxi Wei, Ph.D.

ON RECEIVING THE
2015 PATRICK SOON-SHIONG INNOVATION AWARDS
ARGOMATIC is a technology platform that connects shippers with qualified carriers who have unutilized capacity on their trucks. The company’s core product solves inefficiencies in the less-than-full-truckload markets within 150 miles of Los Angeles, New York and San Francisco.

The local trucking market is highly fragmented, with 90% of carriers operating six trucks or less. Cargomatic aggregates supply and makes it available to shippers via its desktop and mobile applications.

Shippers log onto the Cargomatic website and enter their shipment information. Two hours before the shipment is scheduled to be picked up, the shipment is displayed on an app and a nearby carrier can accept the job using their smartphone.

By tendering shipments in real time, carriers only see shipments that are on or near their existing routes and ready for immediate pickup. This allows them to maximize the space on their trucks and reduce the number of vehicles a shipper needs to have on hand to accommodate peak business cycles.

Every day, tens of thousands of trucks with extra capacity are driving by businesses that have freight that needs to move in the same direction. Simply by connecting these parties through software, Cargomatic can reduce truck emissions by improving the ratio of freight moved per vehicle-mile traveled.

Cargomatic’s app was built for the local, less-than-truckload marketplace. But the company’s engineers have developed a drayage product designed to more efficiently move shipping containers out of the ports. Cargomatic is working in close partnership with the West Basin Container Terminal at the Port of Los Angeles, where it first tested Cargomatic Free Flow - a drayage product designed to more efficiently move shipping containers out of the ports - and is building out its pilot program.

Traditionally, when shipping containers come off a ship, they are placed into long rows of 250-300 containers stacked six-high. When a trucker arrives to pick up a container, crane operators have to dig that container out of the pile. On average, three containers must be moved for every one container delivered. Since displaced containers must be placed back into the row after the desired container is removed, crane operators have to make a total of seven container moves, on average, for every one container delivered.

Cargomatic’s system aims to change that through “free flow.” If a shipper has a certain minimum number of containers on one ship (typically 30-50 containers), a port operator will agree to place those containers in a separate “free flow” pile. Because all of the containers in a free flow pile are headed for one company’s distribution center, it doesn’t matter which container a trucker receives. This arrangement allows top-handlers to “peel off” the first container from the stack and place it directly on a truck, resulting in 1 container delivered for every 1 container moved, or a 700% improvement in operator efficiency.

Jonathan Kessler of Cargomatic
THE PRIVATE BANKING AND INVESTMENT GROUP AT MERRILL LYNCH SALUTES THE PATRICK SOON-SHIONG INNOVATION AWARDS, RECOGNIZING INNOVATION AND ENTREPRENEURSHIP

The Private Banking and Investment Group at Merrill Lynch is committed to supporting individuals and organizations in our community that contribute to enhancing the neighborhoods where we live.

Life’s better when we’re connected®

The Gray Group
Eric Gray
Managing Director – Wealth Management
Private Wealth Advisor
310.407.3979 • eric_gray@ml.com

Merrill Lynch Private Banking and Investment Group
2049 Century Park East
Suite 1100
Los Angeles, CA 90067
AUGMENTED and virtual realities are having “a moment” in the tech world. From the rise and fall of Google Glass to billion dollar acquisitions and valuations, there is no question that the industry is one of the most closely watched and widely discussed.

The augmented reality market is projected to generate $150 billion in revenue by 2020. Most of the hype has been around consumer-facing experiences, and not much attention has been paid to other applications for both hardware and software. There is a huge, un-tapped opportunity around using augmented reality in the workforce, and it is going to have a drastic impact on the way we work in the future.

DAQRI is an augmented reality company powering the future of work through innovative hardware and software products. Its flagship product, the DAQRI Smart Helmet, uses augmented reality technology to improve safety and efficiency for workers on the job and provides unparalleled cost savings for Fortune 500 companies in industrial and manufacturing settings.

DAQRI spent more than a year developing the DAQRI Smart Helmet, a professional-grade head-mounted display for industrial environments. With the Smart Helmet, workers are able to seamlessly connect to their environments, improving productivity, safety and efficiency. Supported by DAQRI’s 4D software, the device is completely hands-free, and allows the wearer to see work instructions in the context of the job being done.

With the Smart Helmet, workers in a variety of industries including aerospace, oil and gas, manufacturing, transportation, power and more can now be connected with the information and environment around them. Workers at complex and dangerous job sites can receive step-by-step instructions on top of real-world objects in their field of vision, or be pinged with instant safety alerts and emergency instructions in the field.

Powering the Smart Helmet is “Intellitrack” the world’s most advanced sensor package. Intellitrack turns any industrial environment into a canvas for 4D content, from in-context training applications to augmented work instructions and beyond. Using DAQRI’s Industrial 4D Studio, its 4D-authoring program, enterprises are able to develop their own workflows using Intellitrack, as well as gather insights into Smart Helmet usage behavior. With a slew of technologically advanced capabilities, including high-resolution 3D sensors, 360 degree navigating cameras and battery life that lasts an entire shift, the Smart Helmet’s technological capabilities are unparalleled.

From training new employees to assembling advanced machinery, the applications for the Smart Helmet are vast. The Smart Helmet will supply workers across a variety of industrial professions with the tools to make their jobs easier and more productive.

As the Los Angeles tech community continues to come of age, DAQRI has been a leader in ensuring that LA remains a hub for innovation. Though AR technology is still in its infancy, DAQRI is working to ensure its widespread adoption, particularly in the industrial space.
JAKKS Pacific Proudly Supports the Patrick Soon-Shiong Innovation Awards and their Commitment to Further Innovation and Entrepreneurship

Congratulations to the Winners & Finalists
Recognizing the need for an environmentally friendly addition to the marine engine industry, Captain Bernardo Herzer has created a new category of cleaner, more reliable outboard engines that eliminate the growing concerns with ethanol problems. With the new and stricter EPA and CARB regulations and lower cost of propane fuel, these more reliable outboards are making boating easier and more fun for the end user. This innovation is the future and one company visionary made it a reality.

In 2012, LEHR launched the 2.5HP and 5.0HP Propane Powered Outboard Engines with immediate acceptance and accolades from the boating world. The LEHR engines utilize LEHR’s award winning gaseous fuel technology to eliminate the environmental detriment of gasoline, extend engine life and reduce the cost of operation.

With the same power and performance and offered at a comparable price to gasoline outboards, the propane engines are superior in that they virtually eliminate particulate emissions, eliminate gasoline pollution in the water, and have zero evaporative emissions from the closed fuel system. In addition, there is no danger of contamination of the water through spillage (propane is not a marine pollutant) and they are cost effective to own and maintain. Propane is a less expensive fuel that does not go bad with time therefore avoiding fuel-related/carbureted maintenance and repairs, particularly with today’s ethanol added fuels. The engines run on LEHR’s new one-pound refillable propane container, or Coleman disposables or attached to standard BBQ propane tanks or any DOT approved propane tanks.

In short, LEHR technology provides its users with equipment that offers full power and performance with reduced emissions, reduced fuel cost, reduced maintenance problems, and lower overall cost of ownership. Unlike gasoline-powered motors, LEHR engines can be safely and quickly refueled without ozone depleting evaporative emissions, spilling or ignition risk.

And that’s not all. Most recently, Captain Herzer and LEHR have continued their innovative success with the release of the world’s first internal battery propane powered outboard engine. Herzer helped develop the marine application for LEHR’s new lithium iron phosphate chemistry technology and now offers this new battery technology on a range of outboards in different horsepower, including a 9.9HP and 15HP. Bringing the environmentally advantageous aspects of this clean alternative fuel with a revolutionary starting option to a broader audience, this new internal battery model is an industry first. Traditional electric start outboards require a large, heavy lead acid or AGM type battery to be carried in the boat along with the associated heavy cables to carry the electrical current to the engine.

LEHR’s new innovation makes use of the latest technology Lithium Iron battery contained inside the housing of the outboard motor itself, thus eliminating the battery and cables inside the boat. The entire system only adds 2 lbs of weight to the outboard. The benefit to a small boat operator looking for portability is obvious. And with an aging active boating population, bringing an electric start option to small, portable self-contained engines is a godsend to many.

From left: David Kostkas of LEHR LLC and Jeff Blum of LEHR LLC
Proud 2015 supporter of the

PATRICK SOON-SHIONG INNOVATION SYMPOSIUM & AWARDS

Congratulations to each deserving finalist. Your pioneering ideas motivate us and affirm our work in IP law.

An acclaimed intellectual property law firm with a service menu tailor made for innovators, entrepreneurs, scientists and business leaders, Fish & Tsang helps make dreams come true one ground-breaking idea after another. Artfully blending innovative approaches with strategic legal acumen, the firm helps revolutionary concepts become global marketplace successes. At Fish & Tsang, your imagination is our inspiration.

The 2015 Nominees for the Patrick Soon-Shiong Innovation & Symposium Awards

Startup in-a-box™

You’re an entrepreneur. You’re ready to change the world.

You’ve got big dreams. We’re here to help.

Making dreams come true is what we do.

Introducing Startup in-a-box™ from Fish & Tsang LLP.

Visit us @ startupinabox.me to apply
Hypertension affects over one billion people on the planet and is one of the leading causes of cardiovascular disease and stroke. Almost 50% of adult hypertensive patients in the U.S. are uncontrolled; that is, they still have high blood pressure.

Thus, there is a significant need for a non-drug therapy option that lowers blood pressure, is minimally invasive for patients, and is cost effective for payers.

In March of 2011, Valencia CEO Jeff Greiner reteamed with CTO Dave Peterson to evaluate if they could take the underlying science of electroacupuncture and mold their Western neuromodulation experience with implantable pacemakers (cochlear implants and spinal cord stimulators) to find a solution that would help improve the lives of millions of people not responding to their blood pressure medications.

Their solution is the radically small, coin-sized Subcutaneous Neuromodulation System (SNS) that stimulates the median nerve in the forearm reducing blood pressure in resistant hypertensive patients.

The underlying science was done by Drs. Li and Longhurst from UC Irvine and establishes the mechanism of action for acupuncture therapy in the treatment of hypertension. These physicians believe and their decades of work show that acupuncture is not mysterious, but neuromodulation. Their research indicates that a low duty cycle can be used for the treatment of chronic conditions, which therefore allows for a once a week, thirty minute stimulation sessions.

Placed in the forearm during a 20-minute office procedure, the coin-sized device stimulates the median nerve at low frequency and low intensity electrical pulses that are comfortable to the patient. The location is optimal because the device sits above the tendons and the fascia where a pocket is naturally formed and just 4 mm away from the target nerve (median nerve). Using local anesthetic, any surgeon or interventionalist can implant the device in a procedure designed by hand surgeon Dr. Subhro Sen of Stanford University. In addition to the device, the cost of the procedure is low given limited time and facility requirements.

Once implanted, the device works by activating the median nerve, sending out a relatively low-powered and well-tolerated electrical stimulus to communicate with the brain.

Valencia’s invention contains the following advantages over present modern technology; it is flat and disk-shaped for retention and stability just under the skin; it is a leadless system with electrodes that are part of the outside housing creating the optimum configured electrical field, its uniquely positioned feed-through offers protection from the rigors of the manufacturing process; and the electronics enable the high impedance watch battery to work.

Unlike most active medical devices on the market, Valencia’s device was also created with the goal of being low cost to produce and therefore, of low cost to the healthcare system. CTO and primary inventor Dave Peterson was able to collaborate with Chief of Mechanical/Materials Engineering Chula Thenuwara in order to produce the device for hundreds of dollars instead of the thousands of dollars larger pacemakers require.
WE CHANGE THE LANDSCAPE BY LOOKING BEYOND THE HORIZON.

As Optimists, we’re driven by a passion to seek new paths. To revolutionize our fields. And to launch the next big thing. Because we believe opportunity lies around every corner, we look beyond our current landscape. We stay ahead of the game. And change it for the world.

What odds will you defy?
X-THERMA INC.
Vallejo

X-THERMA is developing a radical new highway of non-toxic, hyper-effective antifreeze agents to fight unwanted ice formation in regenerative medicine, advanced formulation cosmetics, enhanced quality frozen food, and industrial deicing applications using nature-inspired, biomimetic nanoscience.

Antifreeze agents (AFPs) are critical additives to control unwanted ice growth in the biomedical arena and a wide array of industries (e.g. frozen food, airplane/gas pipeline deicing and engine coolants.) A major chemical breakthrough is demanded because of the limitations of the classic CPAs that have not been greatly improved in the last 50 years, dimethyl sulfoxide (DMSO) and ethylene/propylene glycol, and their adverse toxicity. Nature provides a great solution for arctic species to survive an ice world by producing natural antifreeze proteins (AFPs). These proteins are among the most wanted proteins because of their superior antifreeze performance compared to DMSO. However, extremely limited resources and difficult purification hinders the commercialization of AFPs leading to unreliable worldwide production. AFPs also exhibit a short shelf life and may cause immune reactions in humans.

X-THERMA has a unique solution. Biomimetic nanoscience provides advanced ice-interacting peptidimimetics similar to AFPs, but superior (cost effective, long lasting, non-immunogenic) to offer the first affordable, safe and highly effective CPAs matching AFPs. Series IPs are in formation to protect multiple technologies in material development and a high-throughput instrument, which is a field first. X-THERMA aims to first "reshape" and "expand" rather than "disrupt" the marketplace by offering this new generation of antifreeze additives to drastically improve the performance of current products in the market. X-THERMA has a horizontal integration market strategy, which focuses on maximizing the return and minimizing the risk for its investors.

The global market for Organ/Tissue Transplantation is estimated to be $20 Billion. In the U.S. only 1 in 5 patients can receive a new organ. In January 2015, major government funding agencies (DoD, NASA, NIH, and NSF) fully realized the ultimate solution is an organ/tissue bank and launched a national movement to fund cutting-edge technologies to enable this vision. X-THERMA’s unique development of new CPAs for safe and effective biobanking was awarded a DoD SBIR Phase I grant in 2015. There are other potential markets and industries that can benefit from this technology as well, including the ice cream industry. U.S. annual sales of ice cream exceed $10 billion in revenue. The key to "creamy good" ice cream is small, controlled ice crystal size. An addition of 4 mg/L of AFPs can prevent the formation of large ice crystals that spoil the smooth, silky texture of premium ice cream, which usually has 17% fat content. A small quantity of our material will allow premium ice cream to become “low fat/low carb” and increase attractiveness to health conscious consumers. Most importantly, by enhancing the stability of the ice cream, it could cut the cold chain costs to 10%.

Xiaoxi Wei, Ph.D. of X-Therma Inc.
ATLANTIS TECHNOLOGIES Dana Point

Atlantis Technologies has commercialized an advanced form of capacitive deionization called RDI, or Radial Deionization. The RDI can economically desalinate complex industrial wastewater such as oil/gas produced water, power plant (FGD scrubber blow-down, cooling tower blow-down), mining, and impaired groundwater.

The system is based on the patented RDI super capacitor cylinder. Cylinders can be placed in series to reduce high salinity water and in parallel to treat municipal scale flow-rates. Atlantis’ RDI system can process water with salinity up to 150,000 ppm, high levels of hardness, heavy metals (Hg, Se, U, Ba, Se), and other low solubility species such as calcium sulfate. High flow rates, high clean water recovery, and low maintenance allow for the cost of ownership to be as much as 70% less than existing state of the art technologies.

The base capability of the RDI system along with the potential for improvements 30-60 times current metrics in energy and weight is a significant breakthrough for capacitive deionization and will allow it to meet and exceed the performance metrics of state of the art reverse osmosis, electro dialysis, and thermal systems. Atlantis has deployed multiple field pilots in the oil & gas market, including a trailer mounted system and remote controlled system in the Middle East. The company has also operated long-term studies in-house on produced water. A 4th generation system is currently being introduced. This system has six times flux rate, which reduces the size of the super capacitor needed by a factor of six, reducing the number one cost component of the system.

FOLDED COLOR PACKAGING Corona

Every short-run folding carton job faces the problem of quality traded-off for cost-effective printing solutions. With the cost structure in the packaging and printing industry inherently designed to favor large quantity orders; the larger the order, the lower the price per piece. Therefore, companies that generally need small quantity orders are forever disadvantaged to pay higher prices.

The world has since witnessed considerable improvements in printing presses, numerous new printing solutions and a plethora of acclaimed innovations. Despite the visible improvements in quality due to more sophisticated machines, only few companies can claim to be concurrently cost-effective and quality-conscious. Most companies charge additional fees based on the number of colors printed, and most can’t sufficiently and consistently match Pantone colors. Hence, there has been a need for a cost-effective and high-quality short-run solution that can effectively match Pantone colors.

Thoro Packaging therefore established FoldedColor, a web-to-folding-carton solution based on its groundbreaking innovation of digital-litho technology with seven-color process. This innovation is cost-effective without conceding quality. It is able to constantly match 83% of Pantone colors with color stability and consistency on all printed cartons. On top of all this, it doesn’t cost more to print 1000+ colors on a carton than to print four colors. This is the first-of-its-kind.

No other technology in the world can boast of stable offset printed folding cartons while matching 83% of Pantone colors, high quality, one price no matter how many printed colors, online 3D proofing, immediate pricing, and fast turnaround time, all at once. FoldedColor saves up to 60% of the average industry pricings because of all these efficiencies.
Any of the medications that can potentially make a major improvement in the survival of patients with life-threatening lung conditions are biologics and other agents that require large doses to be delivered directly to the lungs. It is the delivery of these life-saving treatments by aerosol inhalation that presents critical needs that are not well served by current technologies.

Dr. Donovan Yeates of KAER Biotherapeutics Corporation took a new and untried approach. He decided to generate a large liquid aerosol containing the drug, rapidly evaporate this aerosol to a dry powder and then remove the majority of the air from the aerosol using virtual impaction such that a concentrated respirable aerosol was delivered at the output. The Heart Lung and Blood Institute of NIH through Phase I and II SBIR grants supported this novel approach dubbed SUPRAER.

Respirable aerosols of proteins, antibodies, surfactant and other large and small molecules have been successfully aerosolized with SUPRAER at rates up to 200 mg/minute. Molecular or biological functional degradation have not been observed. A solid particle of protein generated by SUPRAER contains 25 times the mass of drug of an equivalent sized 4% solution of an aqueous aerosol. SUPRAER uses a single-pass low-shear nozzle. The final particle size and delivery rate are tailored to the need at hand. Output efficiencies of 65% are attainable.

The system is scalable and can easily be manufactured as an in-hospital device or as an aerosol generation system for home use. The universality of this system enables it to deliver all drugs in solution or suspension.

KAER BIOOTHERAPEUTICS CORPORATION

LUBAX, INC.

Os in five globally suffer from skin disease, such as infections, rashes, ulcers, moles, and cancers, and surveys consistently show that skin disease is the number one reason patients seek health care. Out of 900,000 physicians in the US, however, only 9,600 are dermatologists. Consequently, physicians of all specialties are continuously confronted with the question: “what is this mole (spot, freckle) on my skin?”

To answer this question, physicians face one of the most glaring deficiencies in modern medicine: there has been no diagnostic test for skin. Lubax has now developed such a test.

Lubax is a mobile app that identifies skin diseases instantaneously. Lubax uses a proprietary database of diagnosed skin-lesion images (currently 12,000 images) and a patented computer vision algorithm based on the principles of content-based image retrieval.

The doctor takes a photo of a skin lesion, and Lubax returns best-matching images and their diagnoses from a proprietary database of diagnosed lesions. No additional lenses or lighting is required, only a smart phone is needed. The software is potentially capable of identifying all skin lesions: if Lubax has relevant images in the database, it can identify the skin lesion. A first trial with Stanford and Oxford showed greater than 90% sensitivity and specificity in identifying melanomas (larger than 10mm), which is even more accurate than most dermatologists. Ultimately, Lubax will not just help doctors decide if their patients need to see a dermatologist, but in fact outperform dermatologists in skin check accuracy.
NEURAL ANALYTICS, INC., Los Angeles

Neural Analytics has built a working prototype of the world’s first objective concussion diagnosis and Return-to-Play (RTP) management device. Our approach combines existing medical technology with cutting-edge robotics and data science.

Concussion, also known as a mild traumatic brain injury (mild TBI), impacts between 1.6 and 3.8 million people each year with higher rates in our military and athletic populations.

Neural Analytics’ technology utilizes non-invasive ultrasound to assess the physiological response of patient blood flow to provide an objective measure of concussion. It has been well-documented in academic literature that there is a strong correlation between impaired cerebral blood flow and mild or severe TBI. Neural Analytics developed several proprietary ways to measure the critical components of cerebral blood flow using “off the shelf” technologies. Measuring cerebral hemodynamics objectively using an accurate, portable device for mild TBI diagnosis and RTP decisions is an innovative approach to address these challenges.

No other technology is capable of obtaining direct real-time information about the physiological processes of cerebral blood flow. Neural Analytics’ platform provides a portable, cost-effective, and safe solution allowing for the mass adoption of our technology. Recently, research and development by Neural Analytics has led to support from federal grant agencies, NASA, the US military, and professional sports organizations.

This innovative technology combines existing medical hardware with advanced robotics and data science to address a significant market opportunity. By providing a safe, non-invasive and cost-effective method to obtain objective and actionable information about the brain, Neural Analytics will help to save lives and enable better patient care.
IN the past two decades, research has failed to produce a new drug to treat Alzheimer's disease because: 1) antibodies to clear amyloid plaques and/or tau tangles from the brain were administered to patients with significant cognitive impairment/dementia — too late to reverse the brain damage; 2) gamma or beta enzyme inhibitors were administered to decrease the formation of amyloid42 (primary cause), but these drugs have many side effects due to other effects of the enzymes, and again it is too late for patients with dementia. Recent evidence with two amyloid antibodies suggests that if administered to pre-cognitive impaired people with minimum amyloid deposits, the cognitive impairment/dementia can be prevented along with further amyloid damage.

NeuroGenetic Pharmaceuticals’ discovery program began in 2003 with the goal of selectively preventing the formation of Ab42 (the bad amyloid) without inhibiting important multifunctional enzymes. After screening 100,000 compounds to find one of interest, then synthesizing more than 2000 molecules to optimize the mechanism and drug-like properties, the company found about ten with excellent potency, selectivity for modulating the cleavage enzymes, orally absorbed and brain selectivity. In 2009, the company chose three compounds for toxicology and drug disposition studies, then selected NGP 555 for further development. It has now been shown that NGP 555 selectively and safely modulates rather than inhibits the key enzymes, is well distributed in the brain, is a stable molecule which has been formulated into a capsule for oral dosing.

This innovation has required major persistence, and results continue to be quite encouraging.
HONORING THE MAN
BEHIND MIRACLES

The people behind medical advances can be as extraordinary as the miracles they create. We’re privileged to salute Steven T. Rosen, M.D., on his Lifetime Achievement Award from the Chicago chapter of the Israel Cancer Research Fund. Renowned as one of the best doctors in America, his talents and commitment are blazing new paths in research and treatment at City of Hope, where he serves as provost and chief scientific officer, as well as the Irell & Manella Cancer Center Director’s Distinguished Chair.

City of Hope is a Los Angeles-based independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope’s research and treatment protocols advance care throughout the nation. It is ranked as one of “America’s Best Hospitals” in cancer by U.S. News & World Report.
PATRICK SOON-SHIONG INNOVATION AWARDS 2015

24Hr HomeCare
El Segundo

3DT Holdings, LLC
San Diego

5D Robotics, Inc.
Carlsbad

Absolute Security
International Inc. Dba
Absolute International Security
Covina

Accurate Background
Irvine

Altus Institute
San Diego

Benefunder
San Diego

CalAsia Pharmaceuticals, Incorporated
San Diego

Choice Technology, Inc.
Reno

CONNECT
San Diego

Cynthia Bennett & Associates
San Diego

Employee Loan Solutions, Inc.
San Diego

Everyone Counts, Inc.
San Diego

EvoRx Technologies
Pasadena

Exergy Systems, Inc
Irvine

EyeSonix
Long Beach

FUGU Corporation
Aliso Viejo

GiftSnap, Inc
Irvine

Graphic Armor
Los Angeles

Greenbelt Resources Corporation
Los Angeles

InfoStreet, Inc.
Tarzana

Innovative Neuro
Technologies, Inc. (INT)
Irvine

Thank You!

L.A. is the greatest city in the world. There’s no better way to stay updated on our region’s latest business and economic news than with the Los Angeles Business Journal.

Patrick Soon-Shiong
for nominating the creative team of

Daily Companion®
The Ultimate all-in-one TeleCare and Medical Alert System
Designed to Promote and Protect your Health

MedSign
www.dailycompanion.com - 310.650.0264
<table>
<thead>
<tr>
<th>Company Name</th>
<th>City</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medsign International Corporation</td>
<td>West Palm Beach</td>
</tr>
<tr>
<td>Molecular Assemblies</td>
<td>San Diego</td>
</tr>
<tr>
<td>nCore Communications, Inc.</td>
<td>San Diego</td>
</tr>
<tr>
<td>NeuroRecovery Technologies, Inc.</td>
<td>Los Angeles</td>
</tr>
<tr>
<td>New Matter</td>
<td>Pasadena</td>
</tr>
<tr>
<td>Pardee Properties</td>
<td>Venice</td>
</tr>
<tr>
<td>personalRN</td>
<td>Hermosa Beach</td>
</tr>
<tr>
<td>PlayWerks and WhizGirls Academy</td>
<td>Los Angeles</td>
</tr>
<tr>
<td>PRAXIS BIOSCIENCES, INC.</td>
<td>Irvine</td>
</tr>
<tr>
<td>Science 37, Inc.</td>
<td>Los Angeles</td>
</tr>
<tr>
<td>Secured Universe Inc.</td>
<td>San Diego</td>
</tr>
<tr>
<td>Sentrian</td>
<td>Aliso Viejo</td>
</tr>
<tr>
<td>Sevion Therapeutics</td>
<td>San Diego</td>
</tr>
<tr>
<td>Smart Action Company, LLC</td>
<td>El Segundo</td>
</tr>
<tr>
<td>Steel Glass, The</td>
<td>Valencia</td>
</tr>
<tr>
<td>Stelle Audio</td>
<td>Newport Beach</td>
</tr>
<tr>
<td>Steve Lee &amp; Associates, LLC</td>
<td>Westlake Village</td>
</tr>
<tr>
<td>The Reader Magazine</td>
<td>Redlands</td>
</tr>
<tr>
<td>Trio Hygiene Systems, LLC</td>
<td>Solana Beach</td>
</tr>
<tr>
<td>Twych Innovation, Inc.</td>
<td>Thousand Oaks</td>
</tr>
<tr>
<td>ViaCyte, Inc.</td>
<td>San Diego</td>
</tr>
</tbody>
</table>

**Congratulations to Leo Petrossian and the talented team at Neural Analytics for being named a Finalist for the 2015 Los Angeles Business Journal Patrick Soon-Shiong Innovation Awards.**

“We are reshaping brain health management through innovative products and services.”

*Inspiration starts with you.*

At AT&T we champion creative thinking and technological advancements to create a better, more connected life.

AT&T is proud to support the Patrick Soon-Shiong Innovation Awards.

©2015 AT&T Intellectual Property. All rights reserved. AT&T and the Globe logo are registered trademarks of AT&T Intellectual Property.
PATRICK SOON-SHIONG INNOVATION AWARDS 2015

EVENT SCENE

From left: Eric Gray of Merrill Lynch, David Kostkas of LEHR LLC, Jeff Blum of LEHR LLC, Jonathan Kessler of Cargomatic, Stacy Greiner Chambliss of Valencia Technologies Corporation, Matt Toledo of Los Angeles Business Journal, Dr. Patrick Soon-Shiong of NantWorks, LLC, Jim Hill of KCBS – TV, Regan Wynne of DAQRI, Dana Morgan of DAQRI, Xiaoxi Wei, PH.D. of X-Therma Inc. and Mark Kline of XTherma Inc.
EVENT SCENE